317 related articles for article (PubMed ID: 26018610)
1. Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it!
Kehr E; Masry P; Lis R; Loda M; Taplin ME; Hirsch MS
Histopathology; 2016 Jan; 68(2):303-7. PubMed ID: 26018610
[TBL] [Abstract][Full Text] [Related]
2. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
3. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.
McKay RR; Xie W; Ye H; Fennessy FM; Zhang Z; Lis R; Calagua C; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang PK; Wagner AA; Parsons JK; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
J Urol; 2021 Jul; 206(1):80-87. PubMed ID: 33683939
[TBL] [Abstract][Full Text] [Related]
4. Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy.
Minardi D; Galosi AB; Giannulis I; Montironi R; Polito M; Muzzonigro G
Scand J Urol Nephrol; 2004; 38(1):19-25. PubMed ID: 15204422
[TBL] [Abstract][Full Text] [Related]
5. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
[TBL] [Abstract][Full Text] [Related]
6. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy.
Potter SR; Mangold LA; Shue MJ; Taylor DC; Lecksell KL; Epstein JI; Walsh PC; Partin AW
Cancer; 2000 Dec; 89(12):2577-86. PubMed ID: 11135219
[TBL] [Abstract][Full Text] [Related]
7. HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.
Varinot J; Furudoï A; Drouin S; Phe V; Penna RR; Roupret M; Bitker MO; Cussenot O; Compérat E
Virchows Arch; 2016 May; 468(5):619-22. PubMed ID: 26931741
[TBL] [Abstract][Full Text] [Related]
8. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
9. The immunohistochemical assessment of occult regional lymph node metastases in patients with T3pN0M0 prostate cancer before definitive radiotherapy.
Clobes H; Fossâ SD; Waehre H; Jocham D; Berner A
BJU Int; 2000 Feb; 85(3):270-5. PubMed ID: 10671880
[TBL] [Abstract][Full Text] [Related]
10. Prospective assessment of histological serial sectioning of pelvic lymph nodes in prostate cancer: a cost-benefit analysis.
Schilling D; Hennenlotter J; Gakis G; Schwentner C; Kuehs U; Stenzl A; Sotlar K
BJU Int; 2012 Sep; 110(6 Pt B):E166-71. PubMed ID: 22314026
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor status of lymph node metastases from prostate cancer.
Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
Prostate; 1996 Feb; 28(2):129-35. PubMed ID: 8604394
[TBL] [Abstract][Full Text] [Related]
12. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
14. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes.
Shariat SF; Roudier MP; Wilcox GE; Kattan MW; Scardino PT; Vessella RL; Erdamar S; Nguyen C; Wheeler TM; Slawin KM
Cancer Res; 2003 Aug; 63(15):4662-70. PubMed ID: 12907647
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
16. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
17. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H
Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901
[No Abstract] [Full Text] [Related]
18. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
[TBL] [Abstract][Full Text] [Related]
19. Screening for occult nodal metastasis in localized carcinoma of the prostate.
Gomella LG; White JL; McCue PA; Byrne DS; Mulholland SG
J Urol; 1993 Apr; 149(4):776-8. PubMed ID: 7681116
[TBL] [Abstract][Full Text] [Related]
20. Detection of micro-metastasis using cytokeratins (AE1/AE3) in haematoxylin & eosin-stained N
Sinha GM; Hegde V
Indian J Med Res; 2023 Apr; 157(4):316-321. PubMed ID: 37282394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
